Defective Drug - Rezulin

Rezulin was a drug for thetreatment of Type II Diabetes.Also known as Troglitazone, Rezulin was designed to treat Type II Diabetes at a cellular level. It was put on the market by Parke Davis (a division of Warner Lambert) and marketed by the company as having side effects comparable to placebo. The drug was shown to cause severe liver toxicity and removed from the market in March of 2000.

Littlepage & Booth contends that Parke Davis (now Pfizer) ignored the signals of liver toxicity that were evident in the pre-marketing testing and clinical trials of Rezulin and that the company misled and manipulated the FDA for approval of this drug putting profits over consumer safety.

Littlepage & Booth has tried three of the six Pfizer Rezulin cases to go to trial in the nation over the past year and brought back over 36 million dollars in verdicts.

Rezulin is highly liver toxic and causes elevated liver enzymes which can lead to liver failure necessitating liver transplant or death. The initial symptoms of liver damage are abdominal pain, swelling in the stomach and extremities, brown urine, yellow eyes, extreme fatigue and jaundice.

If you or someone you love took Rezulin or if you would like more information on the drug, please email april@littlepagebooth.com

 

Articles concerning Littlepage & Booth and Rezulin: